Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.

Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company …
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news